%PDF-1.4
%
59 0 obj
<>
endobj
56 0 obj
<>
endobj
113 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2004-03-02T09:34:19Z
2024-03-28T01:20:13-07:00
QuarkXPressª 4.11: AdobePS 8.8.0 (301)
2024-03-28T01:20:13-07:00
application/pdf
Heather
2003-868.april suppl 70
uuid:b207fc78-1dd1-11b2-0a00-9c0927bd3700
uuid:b207fc7b-1dd1-11b2-0a00-5b0000000000
endstream
endobj
45 0 obj
<>
endobj
46 0 obj
<>
endobj
60 0 obj
<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Thumb 33 0 R/Type/Page>>
endobj
1 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 35 0 R/Type/Page>>
endobj
9 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 37 0 R/Type/Page>>
endobj
17 0 obj
<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Thumb 39 0 R/Type/Page>>
endobj
127 0 obj
[131 0 R]
endobj
128 0 obj
<>stream
q
0 0 612 792 re
W n
BT
0.8 g
/T1_0 18 Tf
0.6114 0.7912 -0.7912 0.6114 35.383 35.2215 Tm
(Personal, non-commercial use only. The Journal of Rheumatology. Copyrigh\
t \251 2004. All rights reserved.)Tj
ET
Q
1 g
/GS0 gs
0 792 m
0 792 l
f
q
-1 793 614 -794 re
W n
q
0 792.03 612 -792 re
W n
BT
0 0 0 1 k
/GS1 gs
/T1_1 1 Tf
-0.00011 Tc 0.0351 Tw 10 0 0 10 66 713.1616 Tm
[(W)79.9 (e have recently analyzed results we obtained when we)]TJ
-0.02679 Tw -1.2 -1.2 Td
(applied a set of criteria considering the time to indication for)Tj
0.0867 Tw 0 -1.2 TD
[(THA)-281.9 (in the ECHODIAH study cohort)]TJ
0 Tc 0 Tw 6.5 0 0 6.5 210.2427 692.4616 Tm
(9)Tj
-0.00011 Tc 0.0867 Tw 10 0 0 10 213.4927 689.1616 Tm
[(. )17.7 (W)79.9 (e applied a very)]TJ
0.3118 Tw -15.9493 -1.2 Td
(simple model that considered structural parameters, the)Tj
0.144 Tw T*
[(patient\325)54.8 (s perspective, and the use of concomitant sympto-)]TJ
0.3569 Tw T*
[(matic therapy)64.8 (. )17.7 (T)69.9 (able 1 depicts the grading system we)]TJ
0.17461 Tw T*
(proposed, based on the results of a multivariate analysis.)Tj
0.00211 Tw T*
(Radiographs were performed annually; other variables were)Tj
0.09621 Tw T*
[(obtained at each visit, e.g., \322W)79.7 (ere nonsteroidal antiinflam-)]TJ
0.2896 Tw T*
(matory drugs taken on more than half the days in the)Tj
0.1066 Tw T*
[(previous 3 month period?\323 )17.7 (W)79.9 (e weighted structural change)]TJ
-0.0056 Tw T*
[(less heavily than symptoms. )17.7 (W)79.9 (e found that if a patient had a)]TJ
0.11481 Tw T*
[(score < 40, the probability of under)17.7 (going )17.7 (THA)-310 (during the)]TJ
0.0631 Tw T*
(study was less than 10%, if the score was )Tj
/T1_2 1 Tf
0 Tc 0 Tw 17.3393 0 Td
(\001)Tj
/T1_1 1 Tf
-0.00011 Tc 0.0631 Tw 1.175 0 Td
(40, the likeli-)Tj
0.0266 Tw -18.5143 -1.2 Td
[(hood of )17.7 (THA)-221.8 (exceeded 50% \(Figure 3\). )17.7 (W)79.9 (e do not regard a)]TJ
0.0401 Tw T*
[(cutof)17.7 (f of 40 as an essential breakpoint, but merely consider)]TJ
0.02499 Tw T*
(this approach to be a starting point for discussion. )Tj
0.3376 Tw 1.2 -1.2 Td
[(Finally)64.8 (, I would like to emphasize that we are not)]TJ
0.0836 Tw -1.2 -1.2 Td
[(defining appropriate criteria for )17.7 (THA. International groups)]TJ
0.17191 Tw 26.4 21.6 Td
([Bone and Joint Decade, EuroHip, Outcome Measures in)Tj
0.21741 Tw T*
[(Rheumatology Clinical )17.7 (T)35 (rials \(OMERACT\)] that include)]TJ
0.00841 Tc 0.3665 Tw T*
[(orthopedic sur)17.6 (geons and rheumatologists are currently)]TJ
-0.00011 Tc 0.01871 Tw T*
(addressing that problem. Nor have we addressed the advan-)Tj
0.0567 Tw T*
[(tages and benefits of )17.7 (THA; others are doing that. Rather)39.7 (, it)]TJ
0.3551 Tw T*
(has been our purpose to attempt to develop workable)Tj
0.1608 Tw T*
(outcome measures that will permit the evaluation of new)Tj
0.02499 Tw T*
(therapies for OA.)Tj
/T1_3 1 Tf
0 Tw 0 -2.4 TD
(REFERENCES)Tj
/T1_1 1 Tf
0.02499 Tw 8 0 0 8 325 595.1616 Tm
[(1.)-875.1 (Dougados M, Nguyen M, Berdah L, et al. Evaluation of the )]TJ
1.675 -1.25 Td
[(structure-modifying ef)17.7 (fects of diacerein in hip osteoarthritis:)]TJ
0 -1.25 TD
[(ECHODIAH, a three-year)39.7 (, placebo-controlled trial. )54.8 (Arthritis Rheum)]TJ
0 Tc 0 Tw T*
(2001;44:2539-47.)Tj
-0.00011 Tc 0.0249 Tw -1.675 -1.25 Td
[(2.)-875.1 (Lequesne M, Maheu E, Cadet C, Dreiser RL. Structural ef)17.7 (fect of)]TJ
1.675 -1.25 Td
(avocado/soybean unsaponifiables on joint space loss in)Tj
T*
[(osteoarthritis of the hip. )54.8 (Arthritis Care Res 2002;47:50-8.)]TJ
-1.675 -1.25 Td
[(3.)-875.1 (Auleley GR, Duche )54.8 (A, Drape JL, Dougados M, Ravaud P)110.7 (.)]TJ
1.675 -1.25 Td
(Measurement of joint space width in hip osteoarthritis: influences)Tj
T*
(of joint positioning and radiographic procedure. Rheumatology)Tj
0 Tc 0 Tw T*
(2001;40:414-9.)Tj
-0.00011 Tc 0.02499 Tw -1.675 -1.25 Td
[(4.)-875.1 (Auleley GR, Giraudeau B, Dougados M, Ravaud P)110.7 (. Radiographic)]TJ
1.675 -1.25 Td
(assessment of hip osteoarthritis progression: impact of reading)Tj
T*
[(procedures for longitudinal studies. )54.8 (Ann Rheum Dis 2000;59:422-7.)]TJ
-1.675 -1.25 Td
[(5.)-875.1 (Conrozier )17.7 (T)74 (, Lequesne M, Favret H, et al. Measurement of the )]TJ
1.675 -1.25 Td
[(radiological hip joint space width. )54.8 (An evaluation of various)]TJ
T*
(methods of measurement. Osteoarthritis Cartilage 2001;9:281-6.)Tj
-1.675 -1.25 Td
[(6.)-875.1 (Bellamy N, Kirwan J, Boers M, et al. Recommendations for a core)]TJ
1.675 -1.25 Td
(set of outcome measures for future phase III clinical trials in knee,)Tj
T*
(hip, and hand osteoarthritis. Consensus development at OMERACT)Tj
T*
(III. J Rheumatol 1997;24:799-804.)Tj
-1.675 -1.25 Td
[(7.)-875.1 (Pham )17.7 (T)74 (,)-0.1 ( )17.7 (V)110.8 (an der Heijde D, Lasserre M, et al. Outcome variables for)]TJ
1.675 -1.25 Td
[(osteoarthritis clinical trials: )17.7 (The OMERACT)91.7 (-OARSI set of)]TJ
T*
(responder criteria. J Rheumatol 2003;30:1648-54.)Tj
-1.675 -1.25 Td
[(8.)-875.1 (Dougados M, Gueguen )54.8 (A, Nguyen M, et al. Requirement for total)]TJ
1.675 -1.25 Td
(hip arthroplasty: an outcome measure of hip osteoarthritis? )Tj
T*
(J Rheumatol 1999;26:855-61.)Tj
-1.675 -1.25 Td
[(9.)-875.1 (Maillefert JF)79.7 (, Gueguen )54.8 (A, Nguyen M, et al. )54.8 (A)-220.1 (composite index for)]TJ
1.675 -1.25 Td
(total hip arthroplasty in patients with hip osteoarthritis. )Tj
T*
(J Rheumatol 2002;29:347-52. )Tj
/T1_4 1 Tf
0 Tc 0.0172 Tw -35.6571 20.7585 Td
[(T)91.9 (able 1. )]TJ
/T1_1 1 Tf
-0.00011 Tc 3.7375 0 Td
(Criteria used to define the \322time to indication for total hip arthro-\
)Tj
0.02499 Tw -3.7375 -1.25 Td
[(plasty)64.8 (.\323 From Maillefert JF)79.7 (, )]TJ
/T1_4 1 Tf
[0.2 (et al.)]TJ
/T1_1 1 Tf
13.9707 0 Td
(J Rheumatol 2002; 29:347-52.)Tj
-0.0002 Tc 0 Tw -13.9707 -2.5 Td
[(V)110.7 (ariable)-13114 (Scoring)-5006.8 (Score)]TJ
-0.00011 Tc 0.02499 Tw 0 -2.5 TD
[(Joint space width on last available )-2325.3 (> 2 mm)-5865.3 (0)]TJ
0 Tw 1.1 -1.25 Td
(radiograph)Tj
/T1_2 1 Tf
0 Tc 14.3783 0 Td
(\001)Tj
/T1_1 1 Tf
-0.00011 Tc 0.0251 Tw 1.0988 0 Td
[(2 > 1 mm)-4678.4 (20)]TJ
/T1_2 1 Tf
0 Tc 0 Tw -0.2918 -1.25 Td
(\002)Tj
/T1_1 1 Tf
-0.00011 Tc 0.02499 Tw 1.0988 0 Td
[(1 mm)-5485.4 (35)]TJ
-17.3841 -1.25 Td
[(Patient\325)54.8 (s overall assessment \(none-)]TJ
/T1_2 1 Tf
0 Tc 0 Tw 17.2006 0 Td
(\002)Tj
/T1_1 1 Tf
6.6506 Tc 1.0988 0 Td
(20)Tj
-0.00011 Tc 0.02499 Tw -17.4744 -1.25 Td
[(mild-moderate-severe-very severe\))-2463 (> 2)-6530.6 (1)-0.1 (5)]TJ
-0.825 -1.25 Td
(Lequesne index)Tj
/T1_2 1 Tf
0 Tc 0 Tw 17.2006 0 Td
(\002)Tj
/T1_1 1 Tf
6.6506 Tc 1.0988 0 Td
(20)Tj
0 Tc 0.02499 Tw -0.9689 -1.25 Td
[(> 2)-6530.5 (25)]TJ
-0.00011 Tc -17.3305 -1.25 Td
(NSAID intake in the 3 mo prior)Tj
/T1_2 1 Tf
0 Tc 0 Tw 15.1474 0 Td
(\002)Tj
/T1_1 1 Tf
-0.00011 Tc 0.02499 Tw 1.0988 0 Td
[(1 day/week)-4597.5 (0)]TJ
-15.1463 -1.25 Td
[(to the last visit)-8242.1 (> 1 day/week)-4477.5 (15)]TJ
-1.1 -1.25 Td
(Analgesic intake in the 3 mo)Tj
/T1_2 1 Tf
0 Tc 0 Tw 15.1474 0 Td
(\002)Tj
/T1_1 1 Tf
-0.00011 Tc 0.02499 Tw 1.0988 0 Td
[(1 day/week)-4597.5 (0)]TJ
-15.1463 -1.25 Td
[(prior to the last visit)-6023.7 (> 1 day/week)-4477.5 (10)]TJ
ET
0 0 0 1 K
0.5 w
52.86 454.64 m
293.14 454.64 l
53.14 435.5 m
292.29 435.5 l
52.86 310.64 m
292.86 310.64 l
S
q
/GS0 gs
1.25 TL /Fm0 Do
Q
BT
/T1_4 1 Tf
8 0 0 8 54 103.5341 Tm
[(Figur)36.8 (e 3.)]TJ
/T1_1 1 Tf
0.07581 Tw 4.5 0 Td
(Frequency with which total hip arthroplasty was performed in)Tj
0.0193 Tw -4.5 -1.25 Td
[(patients with cutof)17.7 (f scores < 40 and )]TJ
/T1_2 1 Tf
0 Tc 0 Tw 14.6485 0 Td
(\001)Tj
/T1_1 1 Tf
-0.00011 Tc 0.01939 Tw 1.0875 0 Td
(40, based upon the criteria listed in)Tj
0.0029 Tc 0.37199 Tw -15.736 -1.25 Td
[(T)69.9 (able 1 to define an \322indication for )17.8 (THA\323 among patients in the)]TJ
-0.00011 Tc 0.02499 Tw 0 -1.25 TD
[(ECHODIAH study)64.8 (. From Maillefert, )]TJ
/T1_4 1 Tf
[-0.2 (et al)]TJ
/T1_1 1 Tf
(. J Rheumatol 2002;29:347-52.)Tj
ET
1 w
54 54 m
558 54 l
S
BT
/T1_4 1 Tf
8 0 0 8 54.5 35.9844 Tm
[(Dougados: Outcome measur)36.8 (es for hip OA)]TJ
0 Tc 0 Tw 61.9375 -0.0313 Td
(69)Tj
ET
0 0 0 0 k
/GS0 gs
109.22 59.08 396.48 -10.83 re
f*
0.5 w
109.22 59.08 396.48 -10.83 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 0 0 rg
/GS2 gs
/T1_5 8 Tf
117.48 51 Td
(Personal, non-commercial use only. The Journal of Rheumatology Copyrig\
ht \251 2004. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_6 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
39 0 obj
<>stream
8;Z\7>B7V(%+P5/W9\Pok`)fX);!.jqIh2b??VZ(@)Qu3la$r,C?'O!!C\Dh2&WpI
ZnHEW=sQ:jD/#LN\>G_-:^7D2#cVh!HW9E^FiG`ckpITZ$t*IT[M9FX)Zi%
hBVMY):;@%K^%nc1)aZ9rdcM!PrbS$'G2'ddYZb@ihXu)FR(QXG;?O>U?Ma`NPTsP
cT-$05$hF5OG9!!;'SGC-p5A&ped
F(\s$otNl-PR'J&opcjV15ahKBd>re8$6iCJN\JK;N0XZqcDISDr"R^QDT##jB*qu
C0o/+oF-kC_0Y7p^F6.\)r4HeOM<]T64QN'1S\ur_?&B$1[.nk?a0;7kW#(r9uf'G
OiDUC5:qt4)8-rW47Z6XifUl[RN(Yug`,U?eImra`)Z(ri:"t@^T!h+!)X;.;#~>
endstream
endobj
43 0 obj
[/Indexed/DeviceRGB 255 42 0 R]
endobj
42 0 obj
<>stream
J,g]g+e/h_!_gCtO=0f)$P%cIi8Zdfc5&3j_8$7g.@L`YKUJNGBP\poR=_;Dl'P(T
(7Boo^^S:71(MN]ZQX/+Cbu.lK"p74pe1T%s.DY%&\1TdJhr54.M9au6>79n6`Q:4
PbLSZTLEE(8E@'*1mg_*eTnN*;*'V3+gm-EEetX%;Bo$ur2ss*N`.-!.kG_q6GDD'
dKoL!8Ka#EV,@V!\j8ZFbp6EE<9cn=N6j0nf;(&;QU6bUD')c@\
9-d\DA=cZ0Q>gIM$$;cd2O@&a;X,Nn_aP(]I1aRc(K1^ue>
gF/(+GaKo$qneLWDrQ#;5\S(\$q'4Q,85`-8;S(=Z"WSBOV*FM)4,?B],R
endstream
endobj
24 0 obj
<>stream
H$A
0DO0wR\x )XM.(_DLQ]<ƌփT`UhFFDbl(y0w*!őgF[_ #}
endstream
endobj
23 0 obj
<1.3<>>>
endobj
21 0 obj
<>/ProcSet[/PDF/ImageB]/XObject<>>>
endobj
20 0 obj
<>/Filter/CCITTFaxDecode/Height 726/ImageMask true/Length 5361/Subtype/Image/Type/XObject/Width 1000>>stream
ngAA4;G&:{y!4q#}|EфGi~{k*+A`bu0_w|w7?/Ȁ?2N>j*?צOVҰX.#DR 0~j
uy V"#D! iƚ|:ka#wt/õD:!M#u7Xg^-m_O(=ab>@6u
'|v +1NC>ҹ$L>Pvja>?ڱ_NZT+C@R%{i=VߖqZ s#5Wj};UN.ܛZ᪄Wru{[CQXj/䇫\kc]8D>ֲ8~ؤtAXN`7I?kΫOڵz_ش%=i&{[aAԠ¦@KK@P*vtF$qQK0OM?u^UDQ7T5I? DzAч8Oߒi߄<ߑO"߇iucӵޟMpe-&5i|%Y
SӰO]L],9ˑ\MW,"\sC`rC9XV9+~/q?~uĂxkyUట xⰐWANPU| V9Qi
^DӬ!yH##8n zc9
9,rcQDr*_%>GW:ɾ!˃C P$9!C$&Į#F',ry\THοq#4aw-Z,@2F>~6;\2쐈ͣٴGd8yaa55rrc99NTceneg_2U:#_eg_
"y!D|3dptGDp0GFߐkkC9C9S)(sOοl;_zu/RP莈8h.) "2BlH u"Cr"9+
ҝ~q]sne]w\"-